EQS-News: Change in Redcare Pharmacy’s Managing Board: CFO Jasper Eenhorst to step down.
|
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Personnel
Change in Redcare Pharmacy’s Managing Board: CFO Jasper Eenhorst to step down. Sevenum, the Netherlands, 26 September 2025. After almost six years as CFO, Jasper Eenhorst will leave Redcare Pharmacy to take on new career opportunities. He is stepping down from the Managing Board today, but will remain with the company until the end of this year to support a smooth transition to his successor. Björn Söder, Chairman of the Supervisory Board comments: “On behalf of the entire Supervisory Board, I would like to sincerely thank Jasper for his exceptional commitment and valuable contribution to the company’s successful development and growth during his tenure. Jasper was instrumental in several successful capital market transactions, among others, the placement of €300 million senior unsecured convertible bonds last April which extended the company’s debt maturity and laid a solid basis for further growth. We have developed our business model over the past years and expanded our market leadership - now also in the German prescription market. We have turned Redcare Pharmacy into a profitable growth story ready for the future. This is a natural moment for Jasper to move on. We wish him every success in his next chapters.” The Supervisory Board has already initiated the search for a new CFO and expects it to be concluded soon. Until a successor has been appointed, the CFO’s responsibilities will be assumed on an interim basis by Olaf Heinrich, CEO of Redcare Pharmacy. Jasper Eenhorst states: “It has been a privilege to serve Redcare Pharmacy as CFO during a period of significant growth and transformation. I am grateful for the trust placed in me and for the years I have spent as part of the team. It was truly gratifying, rewarding and memorable, full of exceptional highlights. It is now the right moment for me to take the next step. I will ensure a smooth handover in the coming months and I am confident that the company will continue to thrive and achieve even greater success.” ___ Investor Relations Contact:
Press Contact:
About Redcare Pharmacy. Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers over 13 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
26.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2204666 |
| End of News | EQS News Service |
|
|
2204666 26.09.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 701,01 | 968,06 | 1.060,32 | 1.204,35 | 1.798,76 | 2.370,58 | 3.000,00 | |
| EBITDA1,2 | -18,58 | 15,20 | -38,73 | -29,66 | 39,99 | 29,23 | 63,00 | |
| EBITDA-Margin3 | -2,65 | 1,57 | -3,65 | -2,46 | 2,22 | 1,23 | 2,10 | |
| EBIT1,4 | -33,45 | -0,87 | -65,70 | -69,17 | -17,30 | -38,99 | -8,00 | |
| EBIT-Margin5 | -4,77 | -0,09 | -6,20 | -5,74 | -0,96 | -1,65 | -0,27 | |
| Net Profit (Loss)1 | -36,27 | -16,77 | -74,19 | -77,65 | -11,61 | -46,36 | -19,00 | |
| Net-Margin6 | -5,17 | -1,73 | -7,00 | -6,45 | -0,65 | -1,96 | -0,63 | |
| Cashflow1,7 | -30,37 | 17,80 | 11,64 | -29,11 | 61,46 | 22,13 | 28,00 | |
| Earnings per share8 | -2,78 | -1,17 | -4,15 | -4,32 | -0,73 | -2,27 | -0,92 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Redcare Pharmacy | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2AR94 | NL0012044747 | N.V. | 1.303,64 Mio € | 13.10.2016 | Kaufen | 9F3893WC+F5 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 40,87 | 0,00 | 0,00 | -29,07 | 2,69 | 58,92 | 0,55 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.04.2026 | 06.05.2026 | 29.07.2026 | 28.10.2025 | 04.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -13,73% | -35,42% | -52,26% | -59,08% | +126,25% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
